FDA may complete review of controversial heart laser next month
This article was originally published in Clinica
Executive Summary
After cancelling a hearing before a US FDA dispute panel regarding its marketing application for its controversial heart laser treatment in July this year, CardioGenesis believes the agency may complete its "interactive" review of the application by the middle of next month.